Emily Maass, APRN
Nurse Practitioner · Red Oak, IANPI 1659925600
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 191 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 13.5% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 191 payments — averaging $16.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$427
- Lilly USA, LLC$406
- AbbVie$364
- Bayer$251
- Pfizer$213
- Astellas Pharma US Inc$190
- plus $1K from 21 others
What the payments were for
- Food & beverage$3,156100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 25 | $427 |
| Lilly USA, LLC | 31 | $406 |
| AbbVie | 22 | $364 |
| Bayer | 15 | $251 |
| Pfizer | 11 | $213 |
| Astellas Pharma US Inc | 10 | $190 |
| Novartis | 9 | $172 |
| Mylan Specialty L.p. | 8 | $131 |
| Amgen | 9 | $127 |
| Merck | 7 | $108 |
| Lundbeck LLC | 3 | $80 |
| Phathom Pharmaceuticals, Inc. | 5 | $75 |
| E.r. Squibb & Sons, L.L.C. | 5 | $73 |
| GSK | 5 | $70 |
| AstraZeneca | 4 | $69 |
| Organon | 4 | $62 |
| Actelion Pharmaceuticals US, Inc. | 2 | $54 |
| Boehringer Ingelheim | 3 | $40 |
| Grifols USA, LLC | 2 | $38 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $38 |
| Boston Scientific | 1 | $36 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $32 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| Johnson & Johnson | 2 | $24 |
| Amarin Pharma, Inc. | 1 | $19 |
| Scpharmaceuticals Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
How this compares
$3,156 in reported general payments places this provider in the 95th percentile of 1,346 nurse practitioner providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 68 | $83,228 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 69 | $54,817 |
| JardianceEmpagliflozin | 56 | $51,697 |
| EliquisApixaban | 31 | $38,728 |
| XareltoRivaroxaban | 32 | $27,518 |
| TrulicityDulaglutide | 12 | $26,705 |
| OzempicSemaglutide | 21 | $21,980 |
| FarxigaDapagliflozin Propanediol | 16 | $19,901 |
| Tresiba Flextouch U-100Insulin Degludec | 28 | $15,192 |
| MyrbetriqMirabegron | 11 | $14,522 |
| TradjentaLinagliptin | 22 | $5,359 |
| Pregabalin | 23 | $2,376 |
| Potassium Chloride | 170 | $2,352 |
| Levothyroxine Sodium | 293 | $2,186 |
| Aripiprazole | 12 | $2,079 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $406 | $109,93380 claims |
| Boehringer IngelheimJardiance, Tradjenta | $40 | $57,05678 claims |
| GSKTrelegy Ellipta | $70 | $54,81769 claims |
| PfizerEliquis | $213 | $38,72831 claims |
| Johnson & JohnsonXarelto | $24 | $27,51832 claims |
| Novo NordiskOzempic | $427 | $21,98021 claims |
| AstraZenecaFarxiga | $69 | $19,90116 claims |
| Astellas Pharma US IncMyrbetriq | $190 | $14,52211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,346 nurse practitioner providers in Iowa.
Other nurse practitioner in Red Oak
- Margaret KinneyRed Oak$13K
- Joan SmithRed Oak$3K
- Nicole MorganDes Moines$106K
- Julie CoffeyIowa City$31K
- Mary JohnsonDavenport$30K
- Megan Hart FernandezCedar Rapids$19K
- Carla HuberCedar Rapids$18K
- Beth ChiaWest Des Moines$15K
- Abbey ModlinDes Moines$12K
- Jonathon HenningsWaterloo$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.